Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | HPGD | P15428 | 2/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.63 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 4/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL178010 | 0.87 | CYP3A4 (0.50) | CYP3A4ALDH1A1HPGDTDP1CYP2C19 | |
| SCHEMBL30313140 | 0.87 | CYP3A4 (0.50) | CYP3A4ALDH1A1HPGDTDP1CYP2C19 | |
| SCHEMBL8123499 | 0.85 | CYP3A4 (0.65) | CYP3A4ALDH1A1HPGDTDP1HSD17B10 | |
| SCHEMBL10589697 | 0.85 | CYP3A4 (0.65) | CYP3A4ALDH1A1HPGDTDP1L3MBTL1 | |
| SCHEMBL30832936 | 0.83 | CYP3A4 (0.41) | CYP3A4ALDH1A1HPGDTDP1HTR2A | |
| SCHEMBL6220134 | 0.80 | CYP3A4 (0.46) | CYP3A4ALDH1A1HPGDTDP1MEN1 | |
| SCHEMBL1943486 | 0.78 | CYP3A4 (0.69) | CYP3A4ALDH1A1HPGDTDP1CYP2C19 | |
| SCHEMBL2090152 | 0.78 | CYP2C19 (0.41) | CYP3A4ALDH1A1HPGDHTR2ACYP2C19 | |
| SCHEMBL14992 | 0.78 | CYP3A4 (1.00) | CYP3A4ALDH1A1HPGDTDP1CYP2C19 | |
| SCHEMBL29350162 | 0.78 | CYP3A4 (1.00) | CYP3A4ALDH1A1HPGDTDP1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108250156-B | Cinnamylate oxadiazine derivative and preparation method and application thereof | 华南农业大学 | 2021-07-09 | — | — | CN | disclosed |
| EP-1158985-A4 | OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS | BAYER PHARMACEUTICALS CORP (US) | 2008-03-12 | — | — | EP | disclosed |
| EP-1751155-A1 | SUBSTITUTED AZACHINAZOLINES HAVING AN ANTIVIRAL ACTION | Bayer HealthCare AG (DE) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005113552-A1 | SUBSTITUTED AZACHINAZOLINES HAVING AN ANTIVIRAL ACTION | BAYER HEALTHCARE AG (DE) | 2005-12-01 | — | — | WO | disclosed |
| WO-2002062763-A2 | INHIBITION OF RAF KINASE USING QUINOLYL ISOQUINOLYL OR PYRIDYL UREAS | BAYER CORPORATION (US) | 2002-08-15 | — | — | WO | disclosed |
| US-20020042517-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER CORPORATION | 2002-04-11 | — | — | US | disclosed |
| EP-1158985-A1 | OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS | Bayer Corporation (US) | 2001-12-05 | — | — | EP | disclosed |
| EP-1140840-A1 | -G(V)-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | Bayer Corporation (US) | 2001-10-10 | — | — | EP | disclosed |
| US-20010016659-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-08-23 | — | — | US | disclosed |
| WO-2000041698-A1 | φ-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS | BAYER CORPORATION (US) | 2000-07-20 | — | — | WO | disclosed |
| WO-2000042012-A1 | φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BAYER CORPORATION (US) | 2000-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010016659-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BRAF, RAF1, ARAF | CYP3A4 2260/4885ALDH1A1 1392/4885HPGD 2745/4885 |
| US-20020042517-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BRAF, RAF1, ARAF | CYP3A4 2260/4885ALDH1A1 1392/4885HPGD 2745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.